

ONE HUNDRED FOURTEENTH CONGRESS
Congress of the United States
House of Representatives

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115

Majority (202) 225-2927
Minority (202) 225-3641

April 4, 2016

Mr. Lawrence O. Gostin
Faculty Director, O'Neill Institute for National and Global Health Law
Georgetown University Law Center
600 New Jersey Avenue, N.W.
Washington, DC 20001


Dear Mr. Gostin:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, March 2, 2016, to testify at the hearing entitled "Examining the U.S. Public Health Response to the Zika Virus."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Monday, April 18, 2016. Your responses should be mailed to Giulia Giannangeli, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to Giulia.Giannangeli@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,


Tim Murphy
Chairman
Subcommittee on Oversight and Investigations

cc: Diana DeGette, Ranking Member, Subcommittee on Oversight and Investigations

Attachment

Attachment—Additional Questions for the Record

The Honorable Tim Murphy

1. Now that the Zika Action Plan Summit on April 1, 2016 in Atlanta, GA has passed, do you have any additional concerns or issues that you would like to raise – and that you believe have not been adequately covered thus far – to improve the federal response to Zika?

The Honorable Marsha Blackburn

1. In previous hearings, vector control has been described as “expensive and complicated.” Is vector control more complicated and more expensive than vaccine development?
2. In your opinion, if a vaccine were tested on 5,000 people and proved to be safe and 90 percent effective would that warrant further development? The genetically engineered mosquito has achieved such success in suppressing the *Aedes aegypti* mosquito.
3. How high of a priority should vector control in Puerto Rico be for the federal government? Should the federal government focus more resources on the development and deployment of innovative vector control solutions?
4. In light of the Olympics later this summer, should Brazil be more aggressively deploying innovative solutions, such as genetically modified mosquitoes, to slow the spread of Zika virus?